NHS England Trials AI and Robotics for Lung Cancer Detection

NHS England is set to launch a trial involving a mix of artificial intelligence and robotic assistance aimed at accelerating the detection and diagnosis of lung cancer, which is, as many know, the deadliest cancer type in the UK.

This initiative coincides with the health service’s commitment to providing lung cancer screenings to all smokers and former smokers by 2030. The goal is to identify around 50,000 lung cancer cases by 2035, with about 23,000 of those detected at an earlier stage, potentially saving many lives.

Lung cancer deserves special attention in the government’s upcoming national cancer plan for England, given its status as the leading cancer killer in Britain—a situation largely rooted in high historical smoking rates. The disease currently takes around 33,100 lives each year in the UK, which breaks down to about 91 people daily.

Moreover, lung cancer is a critical area where health disparities are evident—a reflection of wealth inequality. In fact, it contributes to a significant portion of the nine-year life expectancy gap between the most and least deprived areas in England.

NHS leaders are optimistic that employing AI and robotic technology will enable quicker identification of cases, allowing for earlier treatment and greatly improving survival rates. This trial will take place at Guy’s and St Thomas’ NHS trust in London.

According to Prof Peter Johnson, the national clinical director for cancer at NHS England, “This is a glimpse of the future of cancer detection.”

In this trial, AI software will examine lung scans, flagging small lumps—some as tiny as 6mm, about the size of a grain of rice—that are more likely to be cancerous. Following this, a robotic camera will guide miniaturized tools to perform biopsies, allowing for more precise tissue samples to be collected for laboratory analysis. This could enable the removal and examination of hard-to-detect nodules deep within the lungs.

If proven effective, this technology could dramatically change how lung cancer is diagnosed, particularly as the NHS screening program begins to identify more small nodules that would have previously gone unnoticed until much later stages. “For many patients, weeks of repeated scans and procedures could be replaced with a single half-hour cancer biopsy, reducing prolonged uncertainty and avoiding more invasive methods,” NHS England noted.

The team involved in the trial has already conducted approximately 300 robotic biopsies, resulting in 215 patients receiving cancer treatment.

Michelle Mitchell, the chief executive of Cancer Research UK, emphasized the urgency of this issue, stating that while lung cancer is the leading cancer killer, earlier diagnosis can significantly enhance survival rates. She added, “New technologies like this show tremendous promise, and swift testing to confirm their accuracy and benefits for patients in real-world settings is essential, ensuring these innovations reach everyone sooner.”